1. Oski FA, Naiman JL. Hematologic Problems
in the Newborn. 2nd ed. Philadelphia, PA: Saunders; 1972.
2. Palis J, Segel GB. Developmental biology of erythropoiesis. Blood
Rev. 1998;12(2):106-114.
3. McGrath KE, Palis J. Hematopoiesis in the yolk sac: more
than meets the eye. Exp Hematol. 2005;33(9):1021-1028.
4. Bank A. Regulation of human fetal hemoglobin: new players,
new complexities. Blood. 2006;107 (2):435-443.
5. Bard H. Hemoglobin synthesis and metabolism during the neonatal
period. In: Christensen RD, ed. Hematologic Problems of
the Neonate. Philadelphia, PA: Saunders; 2000:365-388.
6. Wood WG. Haemoglobin synthesis during human fetal development. Br
Med Bull. 1976;32(3):282-287.
7. Weatherall DJ, Clegg JB. The Thalassanemia Syndromes.
4th ed. London, UK: Blackwell Science; 2001.
8. Hermansen MC. Nucleated red blood cells in the fetus and
newborn. Arch Dis Child Fetal Neonatal Ed. 2001;84(3):F211-F215.
9. Yeruchimovich M, Dollberg S, Green DW, Mimouni FB. Nucleated
red blood cells in infants of smoking mothers. Obstet Gynecol. 1999;93(3):403-406.
10. Phelan JP, Korst LM, Ahn MO, Martin GI. Neonatal nucleated
red blood cell and lymphocyte counts in fetal brain injury. Obstet Gynecol. 1998;91(4):485-489.
11. Korst LM, Phelan JP, Ahn MO, Martin GI. Nucleated red blood
cells: an update on the marker for fetal asphyxia. Am J
Obstet Gynecol. 1996;175(4 Pt 1):843-846.
12. Ghosh B, Mittal S, Kumar S, Dadhwal V. Prediction of perinatal
asphyxia with nucleated red blood cells in cord blood of newborns. Int
J Gynaecol Obstet. 2003;81(3):267-271.
13. Hanlon-Lundberg KM, Kirby RS. Nucleated red blood cells
as a marker of acidemia in term neonates. Am J Obstet Gynecol. 1999;181(1):196-201.
14. Saracoglu F, Sahin I, Eser E, Gol K, Turkkani B. Nucleated
red blood cells as a marker in acute and chronic fetal asphyxia. Int
J Gynaecol Obstet. 2000;71(2):113-118.
15. Mentzer WC, Glader BE. Erythrocyte disorders in infancy.
In: Taeusch HW, Ballard RA, Gleason CA, eds. Avery’s
Diseases of the Newborn. 8th ed. Philadelphia, PA: Elsevier
Saunders; 2005:1180-1214.
16. Stockman JA, 3rd, Oski FA. RBC values in low-birth-weight
infants during the first seven weeks of life. Am J Dis Child. 1980;134(10):945-946.
17. Kleihauer E, Braun H, Betke K. [Demonstration of
fetal hemoglobin in erythrocytes of a blood smear.] Klin
Wochenschr. 1957;35(12):637-638.
18. Oyelese Y, Smulian JC. Placenta previa, placenta accreta,
and vasa previa. Obstet Gynecol. 2006;107(4):927-941.
19. Plauche WC. Subgaleal hematoma. A complication of instrumental
delivery. JAMA. 1980;244 (14):1597-1598.
20. Steiner LA, Gallagher PG. Erythrocyte disorders in the perinatal
period.
Semin Perinatol. 2007; 31(4):254-261.
[PubMed: 17825683]
21. Diamond LK, Blackfan KD, Baty JM. Erythroblastosis fetalis
and its association with universal edema of the fetus, icterus gravis
neonatorum and anemia of the newborn. J Pediatr. 1932;1(3):269-309.
22. Fung Kee Fung K, Eason E, Crane J, et al. Prevention of
Rh alloimmunization. J Obstet Gynaecol Can. 2003;25(9):765-773.
23. Wible-Kant J, Beer AE. Antepartum Rh immune globulin. Clin
Perinatol. 1983;10(2):343-355.
24. Scott F, Chan FY. Assessment of the clinical usefulness
of the “Queenan” chart versus the “Liley” chart
in predicting severity of rhesus iso-immunization. Prenat
Diagn. 1998;18(11):1143-1148.
25. Moise KJ Jr. Changing trends in the management of red blood
cell alloimmunization in pregnancy. Arch Pathol Lab Med. 1994;118(4):421-428.
26. Kurlat I, Sola A. Neonatal polycythemia in appropriately
grown infants of hypertensive mothers. Acta Paediatr. 1992;81(9):662-664.
27. Ramamurthy RS, Berlanga M. Postnatal alteration in hematocrit
and viscosity in normal and polycythemic infants. J Pediatr. 1987;110(6):929-934.
28. Ramamurthy RS, Brans YW. Neonatal polycythemia: I. Criteria
for diagnosis and treatment. Pediatrics. 1981;68(2):168-174.
29. Brans YW, Shannon DL, Ramamurthy RS. Neonatal polycythemia:
II. Plasma, blood and red cell volume estimates in relation to hematocrit
levels and quality of intrauterine growth. Pediatrics. 1981;68(2):175-182.
30. Schimmel MS, Bromiker R, Soll RF. Neonatal polycythemia:
is partial exchange transfusion justified? Clin Perinatol. 2004;31(3):545-553, ix-x.
31. de Waal KA, Baetrs W, Offringa M. Systematic review of the
optimal fluid for dilutional exchange transfusion in neonatal polycythaemia. Arch
Dis Child Fetal Neonatal Ed. 2006;91(1):F7-F10.
32. Christensen RD, Calhoun DA. Congenital neutropenia. Clin
Perinatol. 2004;31(1):29-38.
33. Tsao PN, Teng RJ, Tang JR, Yau KI. Granulocyte colony-stimulating
factor in the cord blood of premature neonates born to mothers with pregnancy-induced
hypertension.
J Pediatr. 1999; 135(1):56-59.
[PubMed: 10393604]
34. Koenig JM, Christensen RD. Incidence, neutrophil kinetics,
and natural history of neonatal neutropenia associated with maternal
hypertension. N Engl J Med. 1989;321(9):557-562.
35. Kostmann R. Infantile genetic agranulocytosis; agranulocytosis
infantilis hereditaria. Acta Paediatr Suppl. 1956;45(suppl
105):1-78.
36. Maheshwari A, Christensen RD, Calhoun DA. Immune neutropenia
in the neonate.
Adv Pediatr. 2002;49:317-339.
[PubMed: 12214777]
37. Isaacs H Jr. Fetal and neonatal leukemia. J Pediatr
Hematol Oncol. 2003;25(5):348-361.
38. Sande JE, Arceci RJ, Lampkin BC. Congenital and neonatal
leukemia. Semin Perinatol. 1999;23(4): 274-285.
39. Bresters D, Reus AC, Veerman AJ, van Wering ER, van der
Does-van den Berg A, Kaspers GJ. Congenital leukaemia: the Dutch
experience and review of the literature. Br J Haematol. 2002;117(3):513-524.
40. Al-Kasim F, Doyle JJ, Massey GV, Weinstein HJ, Zipursky
A. Incidence and treatment of potentially lethal diseases in transient
leukemia of Down syndrome: Pediatric Oncology Group Study. J
Pediatr Hematol Oncol. 2002;24(1):9-13.
41. Massey GV. Transient leukemia in newborns with Down syndrome. Pediatr
Blood Cancer. 2005;44(1):29-32.
42. Castle V, Andrew M, Kelton J, Giron D, Johnston M, Carter
C. Frequency and mechanism of neonatal thrombocytopenia. J
Pediatr. 1986;108(5 Pt 1):749-755.
43. Uhrynowska M, Maslanka K, Zupanska B. Neonatal thrombocytopenia:
incidence, serological and clinical observations. Am J Perinatol. 1997;14(7):
415-418.
44. Chakravorty S, Murray N, Roberts I. Neonatal thrombocytopenia. Early
Hum Dev. 2005;81(1): 35-41.
45. Wade EE, Rebuck JA, Healey MA, Rogers FB. H(2) antagonist-induced
thrombocytopenia: is this a real phenomenon? Intensive Care
Med. 2002;28(4):459-465.
46. Kaplan C. Alloimmune thrombocytopenia of the fetus and the
newborn. Blood Rev. 2002;16(1):69-72.
47. Lippi G, Salvagno GL, Rugolotto S, et al. Routine coagulation
tests in newborn and young infants. J Thromb Thrombolysis. 2007;24(2):153-155.
48. Andrew M, Paes B, Johnston M. Development of the hemostatic
system in the neonate and young infant. Am J Pediatr Hematol
Oncol. 1990;12(1):95-104.
49. Monagle P, Barnes C, Ignjatovic V, et al. Developmental
haemostasis. Impact for clinical haemostasis laboratories. Thromb
Haemost. 2006;95(2):362-372.
50. Chalmers EA. Neonatal coagulation problems. Arch
Dis Child Fetal Neonatal Ed. 2004;89 (6):F475-F478.
51. Pollmann H, Richter H, Ringkamp H, Jurgens H. When are children
diagnosed as having severe haemophilia and when do they start to bleed?
A 10-year single-centre PUP study. Eur J Pediatr. 1999;158(suppl
3):S166-S170.
52. Conway JH, Hilgartner MW. Initial presentations of pediatric
hemophiliacs. Arch Pediatr Adolesc Med. 1994;148(6):589-594.
53.Chalmers EA. Haemophilia and the newborn. Blood Rev. 2004;18(2):85-92.
54. Grabowski EF, Buonanno FS, Krishnamoorthy K. Prothrombotic
risk factors in the evaluation and management of perinatal stroke. Semin Perinatol. 2007;31(4):243-249.
55. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective
Canadian and international registry. Pediatrics. 1995;96(5
Pt 1):939-943.
56. Hoppe C, Matsunaga A. Pediatric thrombosis. Pediatr
Clin North Am. 2002;49(6):1257-1283.
57. Williams MD, Chalmers EA, Gibson BE. The investigation and
management of neonatal haemostasis and thrombosis.
Br J
Haematol. 2002; 119(2):295-309.
[PubMed: 12406062]
58. Malowany JI, Knoppert DC, Chan AK, Pepelassis D, Lee DS.
Enoxaparin use in the neonatal intensive care unit: experience over
8 years. Pharmacotherapy. 2007;27(9):1263-1271.
59. Andrew ME, Monagle P, deVeber G, Chan AK. Thromboembolic
disease and antithrombotic therapy in newborns. Hematology
Am Soc Hematol Educ Program. 2001:358-374.
60. Brouillard RP. Measurement of red blood cell life-span. JAMA. 1974;230(9):1304-1305.
61. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N
Engl J Med. 2001;344(8): 581-590.
62. Maisels MJ, Kring E. Transcutaneous bilirubin levels in
the first 96 hours in a normal newborn population of > or = 35
weeks’ gestation. Pediatrics. 2006;117(4):1169-1173.
63. Hardy JB, Drage JS, Jackson EC. The First Year of
Life: The Collaborative Perinatal Project of the National Institutes
of Neurological and Communicative Disorders and Stroke. Baltimore,
MD: Johns Hopkins University Press; 1979.
64. Stevenson DK, Fanaroff AA, Maisels MJ, et al. Prediction
of hyperbilirubinemia in near-term and term infants. Pediatrics. 2001;108(1):31-39.
65. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of
a predischarge hour-specific serum bilirubin for subsequent significant
hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. 1999;103(1):6-14.
66. Newman TB, Escobar GJ, Gonzales VM, Armstrong MA, Gardner
MN, Folck BF. Frequency of neonatal bilirubin testing and hyperbilirubinemia
in a large health maintenance organization. Pediatrics. 1999;104(5
Pt 2):1198-1203.
67. Kaplan M, Renbaum P, Levy-Lahad E, Hammerman C, Lahad A,
Beutler E. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency:
a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc
Natl Acad Sci U S A. 1997;94(22):12128-12132.
68. Yamamoto A, Nishio H, Waku S, et al. Gly71Arg mutation of
the bilirubin UDP-glucuronosyltransferase 1A1 gene is associated
with neonatal hyperbilirubinemia in the Japanese population. Kobe
J Med Sci. 2002;48(3-4):73-77.
69. Gourley GR, Arend RA. beta-Glucuronidase and hyperbilirubinaemia
in breast-fed and formula-fed babies. Lancet. 1986;1(8482):644-646.
70. Management of hyperbilirubinemia in the newborn infant 35
or more weeks of gestation. Pediatrics. 2004;114(1):297-316.
71. Shapiro SM, Bhutani VK, Johnson L. Hyperbilirubinemia and
kernicterus. Clin Perinatol. 2006;33(2):387-410.
72. Volpe JJ. Neurology of the Newborn. 4th
ed. Philadelphia, PA: Saunders; 2001.
73. Jiang ZD, Chen C, Liu TT, Wilkinson AR. Changes in brainstem
auditory evoked response latencies in term neonates with hyperbilirubinemia. Pediatr
Neurol. 2007;37(1):35-41.
74. Funato M, Tamai H, Shimada S, Nakamura H. Vigintiphobia,
unbound bilirubin, and auditory brainstem responses. Pediatrics. 1994;93(1):50-53.
75. Nakamura H, Takada S, Shimabuku R, Matsuo M, Matsuo T, Negishi
H. Auditory nerve and brainstem responses in newborn infants with
hyperbilirubinemia. Pediatrics. 1985;75(4):703-708.
76. Xoinis K, Weirather Y, Mavoori H, Shaha SH, Iwamoto LM.
Extremely low birth weight infants are at high risk for auditory
neuropathy. J Perinatol. 2007;27(11):718-723.
77. Ip S, Chung M, Kulig J, et al. An evidence-based review
of important issues concerning neonatal hyperbilirubinemia. Pediatrics. 2004;114(1):e130-e153.
78. Newman TB, Liljestrand P, Jeremy RJ, et al. Outcomes among
newborns with total serum bilirubin levels of 25 mg per deciliter
or more. N Engl J Med. 2006;354(18):1889-1900.
79. Seidman DS, Paz I, Stevenson DK, Laor A, Danon YL, Gale
R. Neonatal hyperbilirubinemia and physical and cognitive performance
at 17 years of age. Pediatrics. 1991;88(4):828-833.
80. Ahlfors CE, Herbsman O. Unbound bilirubin in a term newborn
with kernicterus. Pediatrics. 2003;111(5 Pt 1):1110-1112.
81. Maisels MJ, Newman TB. Kernicterus in otherwise healthy,
breast-fed term newborns. Pediatrics. 1995;96(4
Pt 1):730-733.
82. Johnson LH, Bhutani VK, Brown AK. System-based approach
to management of neonatal jaundice and prevention of kernicterus. J
Pediatr. 2002;140(4):396-403.
83. Suresh GK, Clark RE. Cost-effectiveness of strategies that
are intended to prevent kernicterus in newborn infants. Pediatrics. 2004;114(4):917-924.
84. Linn S, Schoenbaum SC, Monson RR, Rosner B, Stubblefield
PG, Ryan KJ. Epidemiology of neonatal hyperbilirubinemia.
Pediatrics. 1985; 75(4):770-774.
[PubMed: 3982909]
85. Newman TB, Easterling MJ, Goldman ES, Stevenson DK. Laboratory
evaluation of jaundice in newborns. Frequency, cost, and yield. Am
J Dis Child. 1990;144(3):364-368.
86. Ebbesen F, Rasmussen LM, Wimberley PD. A new transcutaneous
bilirubinometer, BiliCheck, used in the neonatal intensive care
unit and the maternity ward. Acta Paediatr. 2002;91(2):203-211.
87. Maisels MJ, Kring E. Transcutaneous bilirubinometry decreases
the need for serum bilirubin measurements and saves money. Pediatrics. 1997;99(4):599-601.
88. Rubaltelli FF, Gourley GR, Loskamp N, et al. Transcutaneous
bilirubin measurement: a multicenter evaluation of a new device. Pediatrics. 2001;107(6):1264-1271.
89. Yasuda S, Itoh S, Isobe K, et al. New transcutaneous jaundice
device with two optical paths. J Perinat Med. 2003;31(1):81-88.
90. Beutler E. G6PD deficiency. Blood. 1994;84 (11):3613-3636.
91. Ahlfors CE. Criteria for exchange transfusion in jaundiced
newborns. Pediatrics. 1994;93(3):488-494.
92. Ennever JF, Costarino AT, Polin RA, Speck WT. Rapid clearance
of a structural isomer of bilirubin during phototherapy.
J
Clin Invest. 1987; 79(6):1674-1678.
[PubMed: 3584465]
93. Vreman HJ, Wong RJ, Stevenson DK. Phototherapy: current
methods and future directions. Semin Perinatol. 2004;28(5):326-333.
94. Maisels MJ, Kring E. Rebound in serum bilirubin level following
intensive phototherapy. Arch Pediatr Adolesc Med. 2002;156(7):669-672.
95. Diamond LK, Allen FH Jr., Thomas WO Jr. Erythroblastosis
fetalis. VII. Treatment with exchange transfusion.
N Engl
J Med. 1951; 244(2):39-49.
[PubMed: 14785788]
96. Gottstein R, Cooke RW. Systematic review of intravenous
immunoglobulin in haemolytic disease of the newborn. Arch
Dis Child Fetal Neonatal Ed. 2003;88(1):F6-F10.
97. Jackson JC. Adverse events associated with exchange transfusion
in healthy and ill newborns. Pediatrics. 1997;99(5):E7.
98. Keenan WJ, Novak KK, Sutherland JM, Bryla DA, Fetterly KL.
Morbidity and mortality associated with exchange transfusion. Pediatrics. 1985;75(2
Pt 2):417-421.
99. Suresh GK, Martin CL, Soll RF. Metalloporphyrins for treatment
of unconjugated hyperbilirubinemia in neonates. Cochrane
Database Syst Rev. 2003(2):CD004207.
100. Kappas A, Drummond GS, Munson DP, Marshall JR. Sn-Mesoporphyrin
interdiction of severe hyperbilirubinemia in Jehovah’s
Witness newborns as an alternative to exchange transfusion. Pediatrics. 2001;108(6):1374-1377.
101. Wong RJ, Bhutani VK, Vreman HJ, Stevenson DK. Pharmacology
review: tin mesoporphyrin for the prevention of severe neonatal
hyperbilirubinemia. NeoReviews. 2007;8(2):e77-e84.